Seven directors out at Anglo-US biotech firm
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE APPOINTMENT of Stuart Wallis, the former Fison chairman, as non-executive chairman of Nashville-based Therapeutic Antibodies coincided with a boardroom clearout which saw the departure of seven directors.
The Anglo-American bio-technology company is best known for its anti- venom serum for snakebites, particularly those of rattlesnakes and the North American viper.
At the same time as the company announced the board restructuring, it also said it was going to appoint a finance director to be based in London. The company, which is based in Tennessee but listed in the UK, plans to move its domicile to London ahead of a planned fund-raising exercise.
"The likely place to raise money is in London and UK institutions like to see British companies run by a Brit," Mr Wallis said.
He added: "I really enjoyed my time at Fisons and I had been thinking I would like to get involved in the pharmaceutical sector again." He said Therapeutic Antibodies had become aware that its board was too large, unwieldy and expensive. The seven directors to go included Professor John Landon, one of the company's founders.
Mr Wallis has enjoyed a terrific run of good fortune. He netted around pounds 1m from his stake in Scholl, the footcare company, when it was sold to Seton Healthier in May.
His stake in LLP, the Lloyd's List publisher, was worth around pounds 2m when the group floated this year. He has also made substantial sums from the sale of Sheffield Forgemasters, the engineering group, and from the takeover of Fisons in 1995.
Shares in Therapeutic Antibodies closed 2.5p up at 77.5p. They were 263.5p last autumn.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments